Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  volasertib
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-15 of 15 for your search:
Start Over
Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2)
Phase: Phase III
Type: Treatment
Status: Closed
Age: 65 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1230.14, 2012-002487-27, NCT01721876
Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia
Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1230.4, 2008-003617-27, NCT00804856
Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1230.5, NCT00824408
Intravenous BI 6727 (Volasertib) in 2nd Line Treatment of Urothelial Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1230.2, NCT01023958
BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1230.18, 2009-015770-35, NCT01121406
Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1230.16, NCT00969553
BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1230.6, 2008-003926-40, NCT00969761
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1230.7, 2008-008304-41, NCT01022853
BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1230.23, 2009-018199-32, NCT01145885
An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1230.20, 2010-019437-97, NCT01206816
BI 6727 (Volasertib) Monotherapy Phase I Trial in Japanese Patients With Advanced Solid Tumours
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 20 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1230.15, NCT01348347
Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)
Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1230.26, NCT01662505
Investigation of Potential Drug-drug Interaction of Volasertib With Itraconazole in Patients With Various Tumours
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1230.24, 2011-002367-23, NCT01772563
Volasertib + Decitabine in Patients With Acute Myeloid Leukemia (AML)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 60 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1230.30, 2013-001752-36, NCT02003573
Volasertib in Combination With Azacitidine in Japanese Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 20 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: 1230.35, NCT02201329
Start Over